华讯
/
最新消息
所属分类概要描述: 1
Huawei and Verizon, patent litigation to reconciliation
Huawei and Verizon, patent litigation to reconciliation
Huawei and Verizon, patent litigation to reconciliation Huawei and Verizon Communications have agreed to settle two lawsuits alleging patent infringement, it was reported on July 12, Beijing time. Over the past 20 years, Huawei has reportedly conducted extensive cross-licensing negotiations with major patent holders in the telecom industry, and has signed more than 100 patent licensing agreements with major ICT manufacturers in the United States, Europe, Japan and South Korea. Together of the two separate cases, already in Texas last week trial. But late on Sunday local time, Huawei and Verizon filed joint motions in two US courts to dismiss both cases, as well as Verizon's counterclaim. In February 2020, Huawei sued Verizon, accusing the company of unauthorized use of more than a dozen Huawei patents in computer networks, download security, and video communications, seeking damages and royalties. In response to today's settlement, Huawei said in a statement: "We are pleased that the two companies have reached a settlement that ends their patent litigation. The terms of the agreement are confidential." People familiar with the matter said huawei's claims could exceed $1 billion. Huawei also noted that it has "more than 100,000 patents in force worldwide, including approximately 10,000 in the United States." Verizon has yet to comment, but said last year that the lawsuits were little more than a public relations stunt. In addition, Verizon has countersued Huawei for patent infringement. "We simply ask Verizon to respect Huawei's investment in research and development and either pay for the use of our patents or refrain from using them," Huawei said last year. Since 2015, huawei won the intellectual property rights of income accumulative total more than $1.4 billion, history accumulated more than 6 billion dollars to pay royalties for legitimate use other company's patent, with 80% paid to American companies. Only high investment can bring high return. The technology that leads the world is huawei's money. Billions and billions of research and development of a technology, with what provided free of charge to each other. So the royalty fees charged by huawei won't give up, how many patent verizon specific to huawei is unknown, but can be seen from the attitude of tough royalties huawei, technology is the absolute principle. With technology, we can promote the development of science and technology, and with technology, we are not afraid of intransigence. Huawei will insist on research and development, more technical breakthrough, form a larger system of patented technology.
查看详情
Huawei and Verizon, patent litigation to reconciliation Huawei and Verizon Communications have agreed to settle two lawsuits alleging patent infringement, it was reported on July 12, Beijing time. Over the past 20 years, Huawei has reportedly conducted extensive cross-licensing negotiations with major patent holders in the telecom industry, and has signed more than 100 patent licensing agreements with major ICT manufacturers in the United States, Europe, Japan and South Korea. Together of the two separate cases, already in Texas last week trial. But late on Sunday local time, Huawei and Verizon filed joint motions in two US courts to dismiss both cases, as well as Verizon's counterclaim. In February 2020, Huawei sued Verizon, accusing the company of unauthorized use of more than a dozen Huawei patents in computer networks, download security, and video communications, seeking damages and royalties. In response to today's settlement, Huawei said in a statement: "We are pleased that the two companies have reached a settlement that ends their patent litigation. The terms of the agreement are confidential." People familiar with the matter said huawei's claims could exceed $1 billion. Huawei also noted that it has "more than 100,000 patents in force worldwide, including approximately 10,000 in the United States." Verizon has yet to comment, but said last year that the lawsuits were little more than a public relations stunt. In addition, Verizon has countersued Huawei for patent infringement. "We simply ask Verizon to respect Huawei's investment in research and development and either pay for the use of our patents or refrain from using them," Huawei said last year. Since 2015, huawei won the intellectual property rights of income accumulative total more than $1.4 billion, history accumulated more than 6 billion dollars to pay royalties for legitimate use other company's patent, with 80% paid to American companies. Only high investment can bring high return. The technology that leads the world is huawei's money. Billions and billions of research and development of a technology, with what provided free of charge to each other. So the royalty fees charged by huawei won't give up, how many patent verizon specific to huawei is unknown, but can be seen from the attitude of tough royalties huawei, technology is the absolute principle. With technology, we can promote the development of science and technology, and with technology, we are not afraid of intransigence. Huawei will insist on research and development, more technical breakthrough, form a larger system of patented technology.
华讯受邀出席2021第一届全国大学生芯片设计暑期学校开班仪式
华讯受邀出席2021第一届全国大学生芯片设计暑期学校开班仪式
7月12日,华讯受邀参加2021第一届全国大学生芯片设计暑期学校开班仪式。本次活动在示范性微电子学院产学融合发展联盟的指导下,由北京大学国家集成电路产教融合创新平台、东南大学微电子学院、南京集成电路培训基地主办,南京集成电路培训基地集成电路培训基地集成电路设计培训部、中科院微电子所南京智能技术研究院承办,同时,也获得了华讯、创意电子等多家企业的支持。 东南大学首席教授、南京集成电路培训基地主任时龙兴,江北新区研创园党工委副书记、南京集成电路培训基地书记周荣,北京大学微纳电子学研究院副院长贾嵩,东南大学电子科学与工程学院副院长徐申及相关企业代表参加,南京华讯知识产权顾问有限公司总经理侯庆辰先生也受邀参加本次活动。 活动上,各大高校老师对此次芯片暑期学校的开办发表了讲话:暑期学校是在国家战略下,通过地方政府、高校、企业等多方共同努力培养集成电路设计人才的一个体现。希望各位同学在暑期学校有所收获,在未来能够成为产业发展的中坚力量。 芯片设计人才是我国集成电路产业高质量发展的核心因素之一。IC设计产业的建设发展离不开优秀人才的支撑,南京集成电路培训基地举办首届全国大学生芯片设计暑期学校,邀请产学界的行业技术专家、高水平教授,围绕行业热点、智能芯片设计主题开展研讨课程、讲座、项目指导、行业精英面对面交流,将行业热点技术及真实项目相结合,以研讨课程与项目实践为手段,并安排芯片设计领域相关技术及工具的培训,主要培养创新型的IC设计人才。 华讯在芯片行业知识产权领域一直有着最专业知识和技能,为多家芯片企业的创新专利助力。此次芯片设计暑期学校的开办,华讯也会尽最大努力为学生提供帮助,为促进中国芯片产业发展出一份力。
查看详情
7月12日,华讯受邀参加2021第一届全国大学生芯片设计暑期学校开班仪式。本次活动在示范性微电子学院产学融合发展联盟的指导下,由北京大学国家集成电路产教融合创新平台、东南大学微电子学院、南京集成电路培训基地主办,南京集成电路培训基地集成电路培训基地集成电路设计培训部、中科院微电子所南京智能技术研究院承办,同时,也获得了华讯、创意电子等多家企业的支持。 东南大学首席教授、南京集成电路培训基地主任时龙兴,江北新区研创园党工委副书记、南京集成电路培训基地书记周荣,北京大学微纳电子学研究院副院长贾嵩,东南大学电子科学与工程学院副院长徐申及相关企业代表参加,南京华讯知识产权顾问有限公司总经理侯庆辰先生也受邀参加本次活动。 活动上,各大高校老师对此次芯片暑期学校的开办发表了讲话:暑期学校是在国家战略下,通过地方政府、高校、企业等多方共同努力培养集成电路设计人才的一个体现。希望各位同学在暑期学校有所收获,在未来能够成为产业发展的中坚力量。 芯片设计人才是我国集成电路产业高质量发展的核心因素之一。IC设计产业的建设发展离不开优秀人才的支撑,南京集成电路培训基地举办首届全国大学生芯片设计暑期学校,邀请产学界的行业技术专家、高水平教授,围绕行业热点、智能芯片设计主题开展研讨课程、讲座、项目指导、行业精英面对面交流,将行业热点技术及真实项目相结合,以研讨课程与项目实践为手段,并安排芯片设计领域相关技术及工具的培训,主要培养创新型的IC设计人才。 华讯在芯片行业知识产权领域一直有着最专业知识和技能,为多家芯片企业的创新专利助力。此次芯片设计暑期学校的开办,华讯也会尽最大努力为学生提供帮助,为促进中国芯片产业发展出一份力。
Kerendia Receives FDA Approval for Slowing chronic kidney disease in Type 2 Diabetes
Kerendia Receives FDA Approval for Slowing chronic kidney disease in Type 2 Diabetes
Kerendia Receives FDA Approval for Slowing chronic kidney disease in Type 2 Diabetes This month FDA announced that they have approved Kerendia (finerenone) tablets for the treatment of patients with chronic kidney disease associated with type 2 diabetes. Kerendia is indicated to delay chronic kidney disease progression. It is able to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adult diabetic patients. Now the drug has also been submitted for marketing authorization in China, European Union and other countries. There are 422 million people with diabetes, and there are up to 40% of all patients with type 2 diabetes develop chronic kidney disease. Diabetes is one of the most common causes of chronic kidney disease and kidney failure. Chronic kidney disease is the gradual loss of kidney function over a period of months to years. It occurs when the kidneys are damaged and cannot filter blood normally, and sometimes can progress to kidney failure. The patients are also at high risk of heart disease because of defective filtering. Kerendia is the first and only nonsteroidal mineralocorticoid receptor antagonist (MRA) for Type 2 diabetic patients with chronic kidney disease, compared to SGLT2 inhibitors, Farxiga (dapagliflozin) and Invokana (canagliflozin). It blocks overactivation of the mineralocorticoid receptor (MR) which contributes to fibrosis and inflammation. The drug is able to target fibrosis and inflammation to slow kidney disease progression. The efficacy of Kerendia was evaluated in a randomized, multicenter, double-blind, placebo-controlled in the phase III trial. There were 5,674 patients in the study. The study found that Kerendia beat placebo when it came to kidney function. That included fending off or slowing progression to kidney failure and kidney death. Furthermore, the study also found that Kerendia reduced the risk of cardiovascular death, non-fatal heart attack, and hospitalization for heart failure.   Kerendia received priority review and fast track designations for their application, and it will be commercially available in the U.S. by the end of July.   資料來源: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease https://www.pharmalive.com/bayers-kerendia-receives-u-s-fda-approval/ https://finance.yahoo.com/news/bayers-kerendia-scores-long-awaited-111105329.html https://www.businesswire.com/news/home/20210709005441/en/Bayer%E2%80%99s-KERENDIA%C2%AE-finerenone-Receives-U.S.-FDA-Approval-for-Treatment-of-Patients-with-Chronic-Kidney-Disease-Associated-with-Type-2-Diabetes https://www.healio.com/news/endocrinology/20200710/finerenone-delays-diabetic-kidney-disease-progression-fideliodkd  
查看详情
Kerendia Receives FDA Approval for Slowing chronic kidney disease in Type 2 Diabetes This month FDA announced that they have approved Kerendia (finerenone) tablets for the treatment of patients with chronic kidney disease associated with type 2 diabetes. Kerendia is indicated to delay chronic kidney disease progression. It is able to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adult diabetic patients. Now the drug has also been submitted for marketing authorization in China, European Union and other countries. There are 422 million people with diabetes, and there are up to 40% of all patients with type 2 diabetes develop chronic kidney disease. Diabetes is one of the most common causes of chronic kidney disease and kidney failure. Chronic kidney disease is the gradual loss of kidney function over a period of months to years. It occurs when the kidneys are damaged and cannot filter blood normally, and sometimes can progress to kidney failure. The patients are also at high risk of heart disease because of defective filtering. Kerendia is the first and only nonsteroidal mineralocorticoid receptor antagonist (MRA) for Type 2 diabetic patients with chronic kidney disease, compared to SGLT2 inhibitors, Farxiga (dapagliflozin) and Invokana (canagliflozin). It blocks overactivation of the mineralocorticoid receptor (MR) which contributes to fibrosis and inflammation. The drug is able to target fibrosis and inflammation to slow kidney disease progression. The efficacy of Kerendia was evaluated in a randomized, multicenter, double-blind, placebo-controlled in the phase III trial. There were 5,674 patients in the study. The study found that Kerendia beat placebo when it came to kidney function. That included fending off or slowing progression to kidney failure and kidney death. Furthermore, the study also found that Kerendia reduced the risk of cardiovascular death, non-fatal heart attack, and hospitalization for heart failure.   Kerendia received priority review and fast track designations for their application, and it will be commercially available in the U.S. by the end of July.   資料來源: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease https://www.pharmalive.com/bayers-kerendia-receives-u-s-fda-approval/ https://finance.yahoo.com/news/bayers-kerendia-scores-long-awaited-111105329.html https://www.businesswire.com/news/home/20210709005441/en/Bayer%E2%80%99s-KERENDIA%C2%AE-finerenone-Receives-U.S.-FDA-Approval-for-Treatment-of-Patients-with-Chronic-Kidney-Disease-Associated-with-Type-2-Diabetes https://www.healio.com/news/endocrinology/20200710/finerenone-delays-diabetic-kidney-disease-progression-fideliodkd  
中国建立药品专利纠纷早期解决机制 发布试行实施办法
中国建立药品专利纠纷早期解决机制 发布试行实施办法
中国建立药品专利纠纷早期解决机制 发布试行实施办法 在新修正的《专利法》相关规定的框架下,国家药监局、国家知识产权局组织制定了《药品专利纠纷早期解决机制实施办法(试行)》,经国务院同意,予7月4日发布并施行。 药品专利纠纷早期解决机制是指将相关药品上市审批程序与相关药品专利纠纷解决程序相衔接的制度。该《办法》旨在为当事人在相关药品上市审评审批环节提供相关专利纠纷解决的机制,保护药品专利权人合法权益,降低仿制药上市后专利侵权风险。 该《办法》的主要内容包括:平台建设和信息公开制度、专利权登记制度、仿制药专利声明制度、司法链接和行政链接制度、批准等待期制度、药品审评审批分类处理制度、首仿药市场独占期制度等。 该《办法》提出,国务院药品监督管理部门组织建立中国上市药品专利信息登记平台,供药品上市许可持有人登记在中国境内注册上市的药品相关专利信息。国家药品审评机构负责建立并维护中国上市药品专利信息登记平台,对已获批上市药品的相关专利信息予以公开。 化学仿制药申请人提交药品上市许可申请时,应当对照已在中国上市药品专利信息登记平台公开的专利信息,针对被仿制药每一件相关的药品专利作出声明。 据了解,可以在中国上市药品专利信息登记平台中登记的具体药品专利包括:化学药品(不含原料药)的药物活性成分化合物专利、含活性成分的药物组合物专利、医药用途专利;中药的中药组合物专利、中药提取物专利、医药用途专利;生物制品的活性成分的序列结构专利、医药用途专利。相关专利不包括中间体、代谢产物、晶型、制备方法、检测方法等的专利。
查看详情
中国建立药品专利纠纷早期解决机制 发布试行实施办法 在新修正的《专利法》相关规定的框架下,国家药监局、国家知识产权局组织制定了《药品专利纠纷早期解决机制实施办法(试行)》,经国务院同意,予7月4日发布并施行。 药品专利纠纷早期解决机制是指将相关药品上市审批程序与相关药品专利纠纷解决程序相衔接的制度。该《办法》旨在为当事人在相关药品上市审评审批环节提供相关专利纠纷解决的机制,保护药品专利权人合法权益,降低仿制药上市后专利侵权风险。 该《办法》的主要内容包括:平台建设和信息公开制度、专利权登记制度、仿制药专利声明制度、司法链接和行政链接制度、批准等待期制度、药品审评审批分类处理制度、首仿药市场独占期制度等。 该《办法》提出,国务院药品监督管理部门组织建立中国上市药品专利信息登记平台,供药品上市许可持有人登记在中国境内注册上市的药品相关专利信息。国家药品审评机构负责建立并维护中国上市药品专利信息登记平台,对已获批上市药品的相关专利信息予以公开。 化学仿制药申请人提交药品上市许可申请时,应当对照已在中国上市药品专利信息登记平台公开的专利信息,针对被仿制药每一件相关的药品专利作出声明。 据了解,可以在中国上市药品专利信息登记平台中登记的具体药品专利包括:化学药品(不含原料药)的药物活性成分化合物专利、含活性成分的药物组合物专利、医药用途专利;中药的中药组合物专利、中药提取物专利、医药用途专利;生物制品的活性成分的序列结构专利、医药用途专利。相关专利不包括中间体、代谢产物、晶型、制备方法、检测方法等的专利。
宜明昂科双特异性抗体IMM2902获批临床
宜明昂科双特异性抗体IMM2902获批临床
发布时间 : 2021-07-02 16:53:12
宜明昂科双特异性抗体IMM2902获批临床 宜明昂科创立于2015年,专注于抗肿瘤免疫治疗产品的开发研究,主要包括双特异性抗体、新型重组蛋白、以及TANKTM细胞治疗等。这些产品的共同特征就是通过激发调动患者自身的免疫系统来发挥抗肿瘤效应,并最终抑制肿瘤细胞的继续生长,逆转由此而导致的一系列恶性症状,从而让患者逐渐回到健康的机体状态。 6月30日,该公司宣布,中国国家药监局(NMPA)批准其CD47x HER2双靶点抗体-受体重组蛋白药物IMM2902开展临床试验,针对适应症为HER2表达的乳腺癌、胃癌、肺癌等实体肿瘤。 CD47在多种肿瘤表面高表达,属于一个泛肿瘤靶点,被部分业内人士认为其有望成为下一个“PD-1”明星靶点。CD47在人体细胞上广泛表达,与巨噬细胞表面的SIRPα受体结合会表达“别吃我”信号。然而,狡猾的肿瘤细胞会通过高表达CD47,逃脱被巨噬细胞吞噬。靶向CD47抗体可以阻断肿瘤细胞上的“别吃我”信号,激活“吃我”信号,从而促使巨噬细胞吞噬肿瘤细胞。 IMM2902项目是基于宜明昂科“mAb-Trap”技术平台研发的、具有全球自主知识产权的新一代双抗类候选药物,针对免疫调节靶点CD47与HER2,通过加速HER2的内吞及降解抑制肿瘤细胞生长;通过阻断“别吃我”信号和激活“吃我”信号激发巨噬细胞对肿瘤细胞的吞噬作用,并将吞噬处理的肿瘤抗原递呈给T细胞,从而发挥强大的肿瘤免疫治疗效应。 宜明昂科公司创始人田文志博士表示,IMM2902是针对CD47和HER2的双靶点特异性分子,通过HER2的高亲和活性使得药物优先与肿瘤细胞结合,同时保留了不与人红细胞结合及避免了“Antigenic sink”等特点,大大加强了双靶点肿瘤特异性协同效应。 此外,宜明昂科的另两款基于CD47靶点的新药也已进入临床研究阶段:一款为IMM01,它是新一代针对CD47靶点的免疫检查点抑制剂,另一款为IMM0306,它是一种靶向CD47和CD20的抗体-受体重组蛋白。田文志博士还表示,宜明昂科一直致力于打造新型免疫调节靶点的抗肿瘤药物研究开发,目前公司数个双靶点特异性蛋白药物均已显示良好的开发前景。宜明昂科将继续深耕抗肿瘤领域,加快研发步伐,开发出一个又一个安全高效的抗肿瘤药物,从而为广大的肿瘤患者带来福音。期待这些在研新药临床研究顺利进行,早日惠及患者。
查看详情
宜明昂科双特异性抗体IMM2902获批临床 宜明昂科创立于2015年,专注于抗肿瘤免疫治疗产品的开发研究,主要包括双特异性抗体、新型重组蛋白、以及TANKTM细胞治疗等。这些产品的共同特征就是通过激发调动患者自身的免疫系统来发挥抗肿瘤效应,并最终抑制肿瘤细胞的继续生长,逆转由此而导致的一系列恶性症状,从而让患者逐渐回到健康的机体状态。 6月30日,该公司宣布,中国国家药监局(NMPA)批准其CD47x HER2双靶点抗体-受体重组蛋白药物IMM2902开展临床试验,针对适应症为HER2表达的乳腺癌、胃癌、肺癌等实体肿瘤。 CD47在多种肿瘤表面高表达,属于一个泛肿瘤靶点,被部分业内人士认为其有望成为下一个“PD-1”明星靶点。CD47在人体细胞上广泛表达,与巨噬细胞表面的SIRPα受体结合会表达“别吃我”信号。然而,狡猾的肿瘤细胞会通过高表达CD47,逃脱被巨噬细胞吞噬。靶向CD47抗体可以阻断肿瘤细胞上的“别吃我”信号,激活“吃我”信号,从而促使巨噬细胞吞噬肿瘤细胞。 IMM2902项目是基于宜明昂科“mAb-Trap”技术平台研发的、具有全球自主知识产权的新一代双抗类候选药物,针对免疫调节靶点CD47与HER2,通过加速HER2的内吞及降解抑制肿瘤细胞生长;通过阻断“别吃我”信号和激活“吃我”信号激发巨噬细胞对肿瘤细胞的吞噬作用,并将吞噬处理的肿瘤抗原递呈给T细胞,从而发挥强大的肿瘤免疫治疗效应。 宜明昂科公司创始人田文志博士表示,IMM2902是针对CD47和HER2的双靶点特异性分子,通过HER2的高亲和活性使得药物优先与肿瘤细胞结合,同时保留了不与人红细胞结合及避免了“Antigenic sink”等特点,大大加强了双靶点肿瘤特异性协同效应。 此外,宜明昂科的另两款基于CD47靶点的新药也已进入临床研究阶段:一款为IMM01,它是新一代针对CD47靶点的免疫检查点抑制剂,另一款为IMM0306,它是一种靶向CD47和CD20的抗体-受体重组蛋白。田文志博士还表示,宜明昂科一直致力于打造新型免疫调节靶点的抗肿瘤药物研究开发,目前公司数个双靶点特异性蛋白药物均已显示良好的开发前景。宜明昂科将继续深耕抗肿瘤领域,加快研发步伐,开发出一个又一个安全高效的抗肿瘤药物,从而为广大的肿瘤患者带来福音。期待这些在研新药临床研究顺利进行,早日惠及患者。
华讯参加南京集成电路产业知识产权联盟发起仪式!
华讯参加南京集成电路产业知识产权联盟发起仪式!
华讯参加南京集成电路产业知识产权联盟发起仪式! 6月21日下午,南京华讯知识产权顾问有限公司(以下简称“华讯”)受邀参加南京集成电路产业知识产权联盟发起仪式暨专利导航成果发布会。本次活动由南京创新周组委会指导,南京市浦口区、南京市市场监督管理局(知识产权局)主办,南京浦口经济开发区管理委员会、南京市浦口区市场监督管理局(知识产权局)承办。 集成电路产业是信息技术产业的核心,是引领新一轮科技革命和产业变革的关键力量,是支撑经济社会发展和保障国家安全的战略性、基础性和先导性产业。 为积极抢抓集成电路产业新一轮发展机遇,推动建立“产、学、研、金、介、用”深度融合的创新体系,华讯连同南大、东大、南理工3所高校以及华天、芯德、凯鼎等5家集成电路产业链企业,在中国专利保护协会、集成电路知识产权联盟、国家知识产权局运促司、省市区知识产权局等单位的指导下,共同签署倡议书,发起倡议组建南京集成电路产业知识产权联盟。 同时,为提升知识产权决策咨询水平,保护知识产权成果、促进新技术转化,浦口区亟需既熟悉集成电路技术,又精通知识产权工作的专家。华讯总经理侯庆辰博士很荣幸的被聘请为浦口区知识产权智库专家。发布会上,浦口区委书记祁豫玮为一批业内权威人士颁发了聘书。侯庆辰先生也将充分发挥智囊团一份子的作用,为集成电路产业高质量发展添砖加瓦。 保护知识产权,就是保护创新,知识产权保护工作关系国家治理体系和治理能力现代化,关系人民生活幸福,关系国家对外开放大局,关系国家安全。华讯也一直秉持着积极发展中国知识产权的态度,为企业、高校的创新专利保驾护航。
查看详情
华讯参加南京集成电路产业知识产权联盟发起仪式! 6月21日下午,南京华讯知识产权顾问有限公司(以下简称“华讯”)受邀参加南京集成电路产业知识产权联盟发起仪式暨专利导航成果发布会。本次活动由南京创新周组委会指导,南京市浦口区、南京市市场监督管理局(知识产权局)主办,南京浦口经济开发区管理委员会、南京市浦口区市场监督管理局(知识产权局)承办。 集成电路产业是信息技术产业的核心,是引领新一轮科技革命和产业变革的关键力量,是支撑经济社会发展和保障国家安全的战略性、基础性和先导性产业。 为积极抢抓集成电路产业新一轮发展机遇,推动建立“产、学、研、金、介、用”深度融合的创新体系,华讯连同南大、东大、南理工3所高校以及华天、芯德、凯鼎等5家集成电路产业链企业,在中国专利保护协会、集成电路知识产权联盟、国家知识产权局运促司、省市区知识产权局等单位的指导下,共同签署倡议书,发起倡议组建南京集成电路产业知识产权联盟。 同时,为提升知识产权决策咨询水平,保护知识产权成果、促进新技术转化,浦口区亟需既熟悉集成电路技术,又精通知识产权工作的专家。华讯总经理侯庆辰博士很荣幸的被聘请为浦口区知识产权智库专家。发布会上,浦口区委书记祁豫玮为一批业内权威人士颁发了聘书。侯庆辰先生也将充分发挥智囊团一份子的作用,为集成电路产业高质量发展添砖加瓦。 保护知识产权,就是保护创新,知识产权保护工作关系国家治理体系和治理能力现代化,关系人民生活幸福,关系国家对外开放大局,关系国家安全。华讯也一直秉持着积极发展中国知识产权的态度,为企业、高校的创新专利保驾护航。
上一页
1
2
...
90

CONTACT

电话:+86 25 56673162 
E-Mail:service@chinaipic.com
地址:江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

公众号二维码

扫一扫,关注我们微博

公众号二维码

扫一扫,关注我们公众号

版权所有 © 南京华讯知识产权顾问有限公司      备案号:苏ICP备15002104号-1      网站建设:中企动力  南京